Related Experiment Video

Updated: Sep 27, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Role of angiogenesis in tumor growth and metastasis

Judah Folkman1

  • 1Departments of Surgery and Cell Biology, Harvard Medical School, Boston, MA, USA.

Seminars in Oncology
|January 8, 2003
PubMed

Insights

Inhibiting tumor angiogenesis, the process of new blood vessel formation, is a promising cancer therapy. Endogenous inhibitors like endostatin and angiostatin show potential in preclinical and early clinical studies with minimal toxicity.

Area of Science:

  • Oncology
  • Cancer Biology
  • Vascular Biology

Background:

  • Angiogenesis is crucial for tumor growth, invasion, and metastasis.
  • Tumors require an "angiogenic switch" to develop beyond a minimal size.
  • Dysregulation of proangiogenic and antiangiogenic factors drives tumor vascularization.

Purpose of the Study:

  • To explore the therapeutic potential of inhibiting tumor angiogenesis.
  • To evaluate the efficacy of endogenous angiogenesis inhibitors.
  • To assess the safety and preliminary results of endostatin and angiostatin in clinical trials.

Main Methods:

  • Investigating strategies for anti-angiogenic agent development.
  • Utilizing endogenous inhibitors such as endostatin and angiostatin.
  • Conducting preclinical studies and Phase 1 clinical trials.

Main Results:

  • Endogenous inhibitors like endostatin and angiostatin can reverse the angiogenic switch.
  • Preclinical data demonstrate endostatin's effectiveness in inhibiting tumor growth and reducing tumor vasculature.
  • Phase 1 clinical trials of endostatin and angiostatin indicate minimal toxicity.

Conclusions:

  • Inhibition of angiogenesis represents a viable strategy for cancer treatment.
  • Endogenous angiogenesis inhibitors offer a promising therapeutic avenue.
  • Endostatin and angiostatin show encouraging safety and efficacy profiles in early clinical evaluation.

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.